ArticleThe Lancet. Haematology2018

Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

Maro Ohanian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.